Netherton Syndrome Market Scope And Analysis

  • Report Code : TIPRE00013771
  • Category : Life Sciences
  • No. of Pages : 150
Buy Now

Netherton Syndrome Market Analysis and Scope (2021-2031)

Buy Now

Netherton Syndrome Market Report Netherton Syndrome Market Size and Share Netherton Syndrome Market Scope and Analysis

Netherton Syndrome Market Report Scope

Report Attribute Details
Market size in 2021 US$ 21.15 Million
Market Size by 2031 US$ 106.34 Billion
Global CAGR (2023 - 2031) 20.6%
Historical Data 2021-2022
Forecast period 2024-2031
Segments Covered By Therapy
  • Keratolytic Agents
  • Oral and Topical Steroids and Retinoids
  • Topical Calcineurin Inhibitors
  • Radiation Therapy
  • Biological Therapy
Regions and Countries Covered North America
  • US
  • Canada
  • Mexico
Europe
  • UK
  • Germany
  • France
  • Russia
  • Italy
  • Rest of Europe
Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific
South and Central America
  • Brazil
  • Argentina
  • Rest of South and Central America
Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa
Market leaders and key company profiles
  • Lifemax Laboratories Inc
  • Azitra Inc
  • Sixera Pharma Ab
  • Dermelix Biotherapeutics
  • Matrisys Bioscience
  • Quoin Pharmaceuticals Ltd
  • Krystal Biotech Inc

    • Netherton Syndrome Market News and Recent Developments

    The Netherton syndrome market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. The following is a list of developments in the market for Netherton syndrome:

    • MatriSys BioScience, a private, clinical-stage pharmaceutical company focused on developing live biotherapeutic products (LBPs) for chronic dermatologic indications provided updates on MSB-2040 used in Netherton’s syndrome receiving regulatory applications (orphan designation in US and EU; IND and CTA) and plans to initiate Phase 1 study in patients in H2 23. (MatriSys BioScience, News, 2023)
    • BioCryst Pharmaceuticals, Inc. announced updates from its drug discovery process and additional therapies from its pipeline that the company will highlight at a Research and Development (R&D). BCX17725 is a potent and selective investigational fusion protein KLK5 inhibitor designed to provide best-in-class, potentially disease-modifying treatment for people with Netherton syndrome. The company looks ahead to begin clinical trials of BCX17725 in 2024. (BioCryst Pharmaceuticals, Inc., Press Release, 2023)
    • National Institute of Health (NIH) awarded ResVita Bio US$ 250,000 Phase 1 SBIR grant to develop RVB-001 as a treatment for Netherton syndrome. (ResVita Bio, News, 2022)
    • ResVita Bio, a cellular therapies startup, announced that the FDA granted Rare Pediatric Disease Designation to RVB-001 for treating Netherton Syndrome. RVB-001 is a genetically engineered probiotic that is topically applied to temporarily colonize the skin and continuously release LEKTI, thereby inhibiting proteolysis and restoring the integrity of the epidermal barrier. (ResVita Bio, News, 2022)

    Netherton Syndrome Market Report Coverage and Deliverables

    The “Netherton SyndromeMarket Size and Forecast (2021–2031)” report provides a detailed analysis of the market covering below areas:

    • Market size and forecast at global, regional, and country levels for all the key market segments covered under the scope
    • Market dynamics such as drivers, restraints, and key opportunities
    • Key future trends
    • Detailed PEST/Porter’s Five Forces and SWOT analysis
    • Global and regional market analysis covering key market trends, major players, regulations, and recent market developments
    • Industry landscape and competition analysis covering market concentration, heat map analysis, prominent players, and recent developments
    • Detailed company profiles